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TRUS-Bx. About 25% of men perceived this 
as a concern, while hematuria and rectal 
bleeding are usually perceived as minor 
discomfort and of little consequence by 
appropriately counseled men.8 Moreover, 
hemoejaculate declines over time from 84% in 
week 1 to 32% after 1 month and is resolved 
after a mean of eight ejaculations.9
Due to  ant imicrobia l-resistance, 
particularly fluoroquinolones, the risk of 
infectious complications is increasing over 
time. This represents the most dangerous 
complication after TRUS-Bx, ranging from 
asymptomatic bacteriuria, urinary tract 
infections and epididymitis to more severe 
ones as sepsis and meningitis.10 The frequency 
of infections requiring hospitalization varies 
between 0.6% and 6.3%.10-12 In the Global 
Prevalence Study of Infections in Urology, 
3.1% required hospitalization after biopsy due 
to febrile-urinary tract infection.10
Many patients experience a worsening of 
lower urinary tract symptoms after TRUS-Bx. 
Urinary retention is usually transient ranging 
from 0.2% to 1.7%.6
TRUS-Bx is associated with significant 
pain and discomfort in a proportion of men. 
Most studies evaluated pain using the visual 
analog scale (0 = none to 10 = worst pain), 
and in a recent study mean score resulted 
1.4  (range 0–5) and 18% of patients would 
not accept a repeat biopsy. 13 Predictors of pain 
include young age, anxiety level, anorectal 
compliance, prostate volume and number of 
biopsy cores; while pain seems not affected by 
using 16- versus 18-gauge needles.
PSYCHOLOGICAL IMPACT OF PROSTATE 
BIOPSY
Some studies have explored the psychological 
impact, including anxiety and depression, 
of TRUS-Bx.14-16 Zisman and coworkers in 
a prospective study on 211 men, found a 
Currently transrectal ultrasound‑guided prostate biopsy  (TRUS‑Bx) is one of 
the most common urological procedures, 
with more than 1 million performed per 
year in Europe and the United States.1 
Among patients undergoing TRUS‑Bx, 
approximately one‑third will receive a 
diagnosis of prostate cancer  (PCa), while 
two‑thirds receive a negative result on 
initial biopsy. Negative biopsy patients 
maintain an estimated risk of repeated 
biopsy of 12% at 1 year and 38% at 5 years. 2 
Standard TRUS‑Bx is likely to systematically 
miss significant tumors, particularly in the 
anterior and apical parts of the gland.3 A 
crucial aim of urologists in the next decade 
is to increase the accuracy of the procedure 
and avoid the use of inappropriate biopsies.
MORBIDITY OF PROSTATIC BIOPSY
Transperineal and transrectal TRUS-Bx 
are associated with a significant morbidity 
with a not negligible risk of hospitalization. 
Visible hematuria following TRUS-Bx is 
reported in a significant number of patients 
ranging between 10% and 84%, according 
to different definitions.4-7 The majority of 
men have mild hematuria, while severe 
bleeding requiring hospitalization occurs 
in  <1% of cases. 6 In a recent randomized 
European Randomized Study of Screening 
for Prostate Cancer (ERSPC) study, hematuria 
lasting  >3  days was seen in 22.6% of men 
and was correlated with increased prostate 
volume.7 The rate of rectal bleeding varies 
between 1.3% and 45%; whereas, severe rectal 
bleeding was reported in 1.3% of patients 
in ERSPC study.7 Many authors found that 
nearly all men reported hemoejaculate after 
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significant reduction in patients well-being, 
both prebiopsy within 30  days, including 
anxiety in 64% of patients.14 Fowler et  al.15 
showed that concerns about diagnosis may 
contribute to anxiety, but that it may occur also 
in patients with negative histology and persist 
up to 12 months. More recently, a prospective 
observational study of 1144 men undergoing 
standard TRUS-Bx  (as part of more than 
100  000 men invited for prostate-specific 
antigen  (PSA) screening) investigated the 
psychological impact of TRUS-Bx, including 
relationships between physical biopsy-related 
symptoms and anxiety/depression using 
the Hospital Anxiety and Depression 
Scale  (HADS).16 Overall, depression and 
anxiety levels were relatively low and stable 
across all time points (approximately 3%–7% 
of men had HADS scores indicating anxiety) 
and confirmed that within 7 days of the biopsy, 
many men reported symptomatic adverse 
effects of the procedure  (as pain, shivers, 
hematuria, hematochezia and hemoejaculate). 
At this time point, before the biopsy result was 
known, men who reported biopsy symptoms 
as a moderate/major problem had markedly 
higher levels of anxiety compared with those 
reporting biopsy symptoms as not a problem/a 
minor problem.16
Interestingly, 35  days after TRUS-Bx 
anxiety was reduced also in patients still 
experiencing adverse events, except for men 
who had received a cancer diagnosis. This 
suggests that better information provision 
in preparation for biopsy may reduce 
unnecessary anxiety and excess healthcare 
contact associated with postbiopsy symptoms.
This study deserves commendation 
for some unique aspects of methodology. 
First, a very high response rate to the 
questionnaires  (95% at 7  days) in such a 
large population  (n  =  1144) testifies the 
accuracy of data collection. Second, the 
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inclusion of the questionnaire score at the 
time of PSA screening, before biopsy was 
indicated, provides the ‘emotional baseline’ 
of patients. Finally, anxiety and depression 
were measured using the HADS that is a 
simple, understandable tool focused on the 
reduction of hedonic capacity, considered 
to be the most sensitive indicators of anxiety 
and depression, regardless of their somatic 
symptoms (as fatigue and loss of libido) that 
can be caused also by organic diseases.17 The 
HADS separately analyze the items for anxiety 
and for depression, and has identified the 
psychological impact of TRUS-Bx primarily 
as a problem of anxiety. However, the HADS 
also has some limitations as it evaluates the 
presence and the amount of anxiety without 
differentiating between trait anxiety (chronic, 
rooted in the behavioral style of the subject) 
and state anxiety  (transient anxious state, 
e.g.  due to TRUS-Bx). A  more specific 
questionnaire for the distinction between 
the two types of anxiety, potentially useful 
for future evaluations, is the ‘State and Trait 
Anxiety Inventory’ (STAY).18
The psychological impact of TRUS-Bx 
along with its morbidity represents a 
further limitation and acts against its wide 
use as a main diagnostic tools and even 
more during active surveillance protocols, 
where rebiopsy is contemplated as in the 
Prostate Cancer Research International: active 
Surveillance  (PRIAS) study where repeat 
biopsies are scheduled after 1, 4 and 7 years.19
STRATEGIES TO IMPROVE TRUS‑BX 
IMPACT
Various strategies have been proposed 
to reduce physical and psychological 
consequences of TRUS-Bx. Infectious 
complications can be reduced by switching/
expanding the antimicrobial regimen, with 
rectal cleansing with povidone-iodine prior 
to procedures or with targeted prophylaxis 
after rectal swab cultures.20-22 A case-control 
retrospective analysis compared a group of 
patients treated with standard prophylaxis 
consisting of 3  days of ciprofloxacin or 
trimethoprim/sulfamethoxazole to another 
‘augmented’ with one dose of intramuscular 
gentamicin before biopsy, and found a 
decrease in hospitalization from 3.8% to 
0.6%.20 The efficacy of prophylaxis with double 
antibiotic was also confirmed in other studies, 
in which amoxicillin-clavulanate or cefoxitin, 
or aminoglycosides were added to the standard 
quinolone.21 Potential drawback of augmented 
prophylaxis includes increased costs, side 
effects and the risk for future antimicrobial 
resistances. Nevertheless, it resulted as 
cost-effective in preliminary analysis.20 A 
Cochrane review showed that enema plus 
antibiotics can reduce the risk of bacteremia 
compared with antibiotics alone, although 
there were no differences in febrile-urinary 
tract infection.22 Some studies assessed 
whether the biopsy approach (transperineal 
vs transrectal) could influence the infection 
rate. Shen et al. did not find any qualitative 
difference in the infection rate between 
the two different approaches.4 Another 
common post TRUS-Bx complication is pain. 
Strategies to reduce pain include intrarectal 
creams, periprostatic nerve blockade (PPNB), 
lidocaine suppositories and sedoanalgesia, 
and should be chosen according to patient’s 
tolerance to pain, anxiety and sociocultural 
factors.23 Some authors have proposed 
anxiety-reducing instruments such as 
music or distraction, which seems to reduce 
psychological perception of pain.24 An 
accurate pre-TRUS-Bx counseling and 
reassurance about the normality of certain side 
effects, such as hemoejaculate, hematuria and 
fever, have proved to reduce the psychological 
impact (anxiety) caused by these side effects.16
REDUCING THE NEED FOR TRUS‑BX
Some new laboratory and imaging instruments 
may help to reduce the use of diagnostic biopsy 
and rebiopsy. Several studies demonstrated 
that multiparametric prostate MRI (MP-MRI) 
is sensitive and specific for PCa detection, 
with an accuracy that increases with tumor 
grade and size.25,26 Kirkham et  al. reported 
a >80% sensitivity in detection of a Gleason 
4  +  3 tumor sized  ≥0.2 cm3  (equivalent to 
a 7 mm sphere) or a Gleason 3  +  4 tumor 
sized ≥0.5 cm3 (equivalent to a 10 mm sphere).25 
Whereas, sensitivity resulted significantly lower 
for Gleason 3  +  3 tumors and the majority 
of small, low-grade  PCas can be missed by 
MP-MRI, but these tumors are supposed to be 
clinically insignificant.26 Moreover, in patients 
with previously negative biopsies and clinical 
progression, MP-MRI may detect missed 
tumors (often anterior) in up to 40% of cases.3
As a consequence, many authors believe 
that, in the future, the use of MP-MRI 
will avoid many unnecessary diagnostic 
biopsies, avoid false negative results, improve 
selection for surveillance, improve local 
staging and planning of therapy in men with 
intermediate-high risk PCa. To achieve these 
goals the definition of the correct detection 
protocol that can include diffusion-weighted 
and dynamic contrast-enhanced sequences as 
well as the definition of the scoring system to 
be used for the interpretation and reporting 
of MP-MRI needs to be clarified.
Several papers reported that serum 
isoforms of PSA and their derivatives, as 
p2PSA, %p2PSA and prostate health index 
may improve the clinical prediction of PCa, 
decrease the recourse to diagnostic biopsies 
and avoid unnecessary repeat biopsies.27 
Even more interestingly, Truong et al. showed 
that a novel combination of field defect 
DNA methylation markers could predict 
the presence of PCa in histologically normal 
TRUS-Bx cores (negative predictive value of 
0.909).28
The role of TRUS-Bx has changed over 
time. Its importance has evolved from pure 
cancer detection to assisting clinical patient 
management; however, it is associated with 
significant morbidity and increased level of 
anxiety. Therefore, maximum efforts should be 
concentrated to reduce biopsy adverse effects, 
to improve selection for TRUS-Bx using novel 
cancer-specific biomarkers and imaging, and 
eventually to replace TRUS-Bx with promising 
noninvasive diagnostic tools such as MP-MRI, 
both for diagnosis and follow-up of patients 
under active surveillance.
REFERENCES
1 Williamson DA, Roberts SA, Paterson DL, Sidjabat H, 
Silvey A, et al. Escherichia coli bloodstream infection 
after transrectal ultrasound‑guided prostate biopsy: 
implications of fluoroquinolone‑resistant sequence 
type 131 as a major causative pathogen. Clin Infect 
Dis 2012; 54: 1406–12.
2 Litwin MS, Saigal CS, Beerbohm EM. The burden 
of urologic diseases in America. J Urol 2005; 
173: 1065–6.
3 Ouzzane A, Puech P, Lemaitre L, Leroy X, Nevoux P, 
et al. Combined multiparametric MRI and targeted 
biopsies improve anterior prostate cancer detection, 
staging, and grading. Urology 2011; 78: 1356–62.
4 Shen PF, Zhu YC, Wei WR, Li YZ, Yang J, et al. The 
results of transperineal versus transrectal prostate 
biopsy: a systematic review and meta‑analysis. Asian 
J Androl 2012; 14: 310–5.
5 Pinkhasov GI, Lin YK, Palmerola R, Smith P, Mahon F, 
et al. Complications following prostate needle 
biopsy requiring hospital admission or emergency 
department visits ‑experience from 1000 consecutive 
cases. BJU Int 2012; 110: 369–74.
6 Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, 
et al. Systematic review of complications of prostate 
biopsy. Eur Urol 2013; 64: 876–92.
7 Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, 
Schrder FH. Complication rates and risk factors of 
5802 transrectal ultrasound‑guided sextant biopsies 
of the prostate within a population‑based screening 
program. Urology 2002; 60: 826–30.
8 Rosario DJ, Lane JA, Metcalfe C, Donovan JL, 
Doble A, et al. Short term outcomes of prostate 
biopsy in men tested for cancer by prostate specific 
antigen: prospective evaluation within ProtecT study. 
BMJ 2012; 344: d7894.
9 Manoharan M, Ayyathurai R, Nieder AM, Soloway MS. 
Hemospermia following transrectal ultrasound‑guided 
prostate biopsy: a prospective study. Prostate Cancer 
Prostatic Dis 2007; 10: 283–7.
10 Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, 
Çek M, et al. GPIU investigators. Infective complications 
after prostate biopsy: outcome of the Global Prevalence 
Study of Infections in Urology (GPIU) 2010 and 2011, 
 
Invited Research Highlight
417
Asian Journal of Andrology 
a prospective multinational multicentre prostate biopsy 
study. Eur Urol 2013; 63: 521–7.
11 de Jesus CM, Correa LA, Padovani CR. Complications 
and risk factors in transrectal ultrasound‑guided prostate 
biopsies. Sao Paulo Med J 2006; 124: 198–202.
12 Otrock ZK, Oghlakian GO, Salamoun MM, Haddad M, 
Bizri AR. Incidence of urinary tract infection following 
transrectal ultrasound guided prostate biopsy at 
a tertiary‑care medical center in Lebanon. Infect 
Control Hosp Epidemiol 2004; 25: 873–7.
13 Kahriman G, Donmez H, Mavili E, Ozcan N, 
Yilmaz SP, et al. Transrectal ultrasound guided 
multi‑core prostate biopsy: pain control: results of 
106 patients. J Clin Ultrasound 2011; 39: 270–3.
14 Zisman A, Leibovici D, Kleinmann J, Siegel YI, 
Lindner A. The impact of prostate biopsy on patient 
well‑being: a prospective study of pain, anxiety and 
erectile dysfunction. J Urol 2001; 165: 445–54.
15 Fowler FJ Jr, Barry MJ, Walker‑Corkery B, Caubet JF, 
Bates DW, et al. The impact of a suspicious prostate 
biopsy on patients’ psychological, socio‑behavioral, 
and medical care outcomes. J Gen Intern Med 2006; 
21: 715–21.
16 Wade J, Rosario DJ, Macefield RC, Avery KN, 
Salter CE, et al. Psychological impact of prostate 
biopsy: physical symptoms, anxiety, and depression. 
J Clin Oncol 2013; 31: 4235–41.
17 Zigmond AS, Snaith RP. The hospital anxiety and 
depression scale. Acta Psychiatr Scand 1983; 
67: 361–70.
18 Spielberger CD. State‑Trait Anxiety and interactional 
psychology. In: Endler M, Endler NS, editors. 
Personality at the crossroads: Current issues in 
interactional psychology. Hillsdale: Erlbaum; 1977.
19 Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, et al. Active 
surveillance for low‑risk prostate cancer worldwide: the 
PRIAS study. Eur Urol 2013; 63: 597–603.
20 Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, 
et al. Reduction in hospital admission rates due to 
post‑prostate biopsy infections after augmenting 
standard antibiotic prophylaxis. J Urol 2013; 
189: 535–40.
21 Ho HS, Ng LG, Tan YH, Yeo M, Cheng CW. Intramuscular 
gentamicin improves the efficacy of ciprofloxacin as an 
antibiotic prophylaxis for transrectal prostate biopsy. 
Ann Acad Med Singapore 2009; 38: 212–6.
22 Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic 
prophylaxis for transrectal prostate biopsy. Cochrane 
Database Syst Rev 2011: CD006576.
23 Cormio L, Pagliarulo V, Lorusso F, Selvaggio O, 
Perrone A, et al. Combined perianal‑intrarectal (PI) 
lidocaine‑prilocaine (LP) cream and lidocaine‑ketorolac 
gel provide better pain relief than combined PI LP 
cream and periprostatic nerve block during transrectal 
prostate biopsy. BJU Int 2012; 109: 1776–80.
24 Valet M, Sprenger T, Boecker H, Willoch F, 
Rummeny E, et al. Distraction modulates connectivity 
of the cingulo‑frontal cortex and the midbrain during 
pain–an fMRI analysis. Pain 2004; 109: 399–408.
25 Kirkham AP, Haslam P, Keanie JY, McCafferty I, 
Padhani AR, et al. Prostate MRI: who, when, and 
how? Report from a UK consensus meeting. Clin 
Radiol 2013; 68: 1016–23.
26 Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS. 
Prostate cancer foci detected on multiparametric 
magnetic resonance imaging are histologically distinct 
from those not detected. J Urol 2012; 187: 2032–8.
27 Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, 
et al. A multicenter study of [‑2]pro‑prostate specific 
antigen combined with prostate specific antigen and 
free prostate specific antigen for prostate cancer 
detection in the 2.0 to 10.0 ng/ml prostate specific 
antigen range. J Urol 2011; 185: 1650–5.
28 Truong M, Yang B, Livermore A, Wagner J, 
Weeratunga P, et al. Using the epigenetic field defect 
to detect prostate cancer in biopsy negative patients. 
J Urol 2013; 189: 2335–41.
How to cite this article: Minervini A, 
Vittori G, Siena G, Carini M. Morbidity and 
psychological impact of prostate biopsy: 
the future calls for a change. Asian J 
Androl 28 March 2014. doi: 10.4103/1008-
682X.126388. [Epub ahead of print]
